Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14:130–46. https://doi.org/10.1038/nrd4504

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bellan C, De Falco G, Lazzi S, Micheli P, Vicidomini S, Schurfeld K, et al. CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation. J Pathol. 2004;203:946–52. https://doi.org/10.1002/path.1588

Article  CAS  PubMed  Google Scholar 

Falco GD, Bellan C, D’Amuri A, Angeloni G, Leucci E, Giordano A, et al. Cdk9 regulates neural differentiation and its expression correlates with the differentiation grade of neuroblastoma and PNET tumors. Cancer Biol Ther. 2005;4:277–81. https://doi.org/10.4161/cbt.4.3.1497

Article  PubMed  Google Scholar 

Simone C, Giordano A. Abrogation of signal-dependent activation of the cdk9/cyclin T2a complex in human RD rhabdomyosarcoma cells. Cell Death Differ. 2007;14:192–5. https://doi.org/10.1038/sj.cdd.4402008

Article  CAS  PubMed  Google Scholar 

Sonawane YA, Taylor MA, Napoleon JV, Rana S, Contreras JI, Natarajan A. Cyclin dependent kinase 9 inhibitors for cancer therapy: miniperspective. J Medicinal Chem. 2016;59:8667–84. https://doi.org/10.1021/acs.jmedchem.6b00150

Article  CAS  Google Scholar 

Robb CM, Kour S, Contreras JI, Agarwal E, Barger CJ, Rana S, et al. Characterization of CDK (5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy. Oncotarget. 2018;9:5216–32. https://doi.org/10.18632/oncotarget.23749

Article  PubMed  Google Scholar 

Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer. 2002;2:910–7. https://doi.org/10.1038/nrc950

Article  CAS  PubMed  Google Scholar 

Xu H, Yu S, Liu Q, Yuan X, Mani S, Pestell RG, et al. Recent advances of highly selective CDK4/6 inhibitors in breast cancer. J Hematol Oncol. 2017;10:1–12. https://doi.org/10.1186/s13045-017-0467-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Glaviano A, Wander SA, Baird RD, Yap KCH, Lam HY, Toi M, et al. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment. Drug Resistance Updates. 2024;76:101103 https://doi.org/10.1016/j.drup.2024.101103

Article  CAS  PubMed  Google Scholar 

Li Q, Jiang B, Guo J, Shao H, Priore ISD, Chang Q, et al. INK4 tumor suppressor proteins mediate resistance to CDK4/6 kinase inhibitors. Cancer Discov. 2022;12:356–71. https://doi.org/10.1158/2159-8290.CD-20-1726

Article  CAS  PubMed  Google Scholar 

Álvarez-Fernández M, Malumbres M. Mechanisms of sensitivity and resistance to CDK4/6 inhibition. Cancer Cell. 2020;37:514–29. https://doi.org/10.1016/j.ccell.2020.03.010

Article  CAS  PubMed  Google Scholar 

Pandey K, An HJ, Kim SK, Lee SA, Kim S, Lim SM, et al. Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review. Int J Cancer. 2019;145:1179–88. https://doi.org/10.1002/ijc.32020

Article  CAS  PubMed  PubMed Central  Google Scholar 

Radu A, Neubauer V, Akagi T, Hanafusa H, Georgescu MM. PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol Cell Biol. 2003;23:6139–49. https://doi.org/10.1128/MCB.23.17.6139-6149.2003

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng X, Zhao JX, Dong F, Cao X-C. ARID1A mutation in metastatic breast cancer: a potential therapeutic target. Front Oncol. 2021;11:759577 https://doi.org/10.3389/fonc.2021.759577

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malumbres M, Sotillo R, Santamaría D, Galan J, Cerezo A, Ortega S, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell. 2004;118:493–504. https://doi.org/10.1016/j.cell.2004.08.002

Article  CAS  PubMed  Google Scholar 

Maurer B, Brandstoetter T, Kollmann S, Sexl V, Prchal-Murphy M. Inducible deletion of CDK4 and CDK6 - deciphering CDK4/6 inhibitor effects in the hematopoietic system. Haematologica. 2021;106:2624–32. https://doi.org/10.3324/haematol.2020.256313

Article  CAS  PubMed  Google Scholar 

Rana S, Bendjennat M, Kour S, King HM, Kizhake S, Zahid M, et al. Selective degradation of CDK6 by a palbociclib based PROTAC. Bioorg Med Chem Lett. 2019;29:1375–79. https://doi.org/10.1016/j.bmcl.2019.03.035

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haid RTU, Reichel A. A mechanistic pharmacodynamic modeling framework for the assessment and optimization of proteolysis targeting chimeras (PROTACs). Pharmaceutics. 2023;15:195 https://doi.org/10.3390/pharmaceutics15010195

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang B, Wang ES, Donovan KA, Liang Y, Fischer ES, Zhang T, et al. Development of dual and selective degraders of cyclin-dependent Kinases 4 and 6. Angew Chem Int Ed Engl. 2019;58:6321–26. https://doi.org/10.1002/anie.201901336

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pu C, Liu Y, Deng R, Xu Q, Wang S, Zhang H, et al. Development of PROTAC degrader probe of CDK4/6 based on DCAF16. Bioorg Chem. 2023;138:106637 https://doi.org/10.1016/j.bioorg.2023.106637

Article  CAS  PubMed  Google Scholar 

Chen P, Cho-Schultz P, Deal JG, Gallego GM, Jalaie M, Kania RS, et al. 2-Amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors. 2019;WO/2019/207463. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019207463

Liu J, Plewe MB, Han X, Na J, Lee MR, Zhang C, et al. Modified proteins and protein binders and degraders. 2024;WO 2024/056077 A1. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2024056077

Detailed experimental information is available in Supplementary Information.

Petzold G, Fischer ES, Thoma NH. Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase. Nature. 2016;532:127–30. https://doi.org/10.1038/nature16979

Article  CAS  PubMed  Google Scholar 

Robbins DW, Peng G, Mihalic J, Sands AT Bifunctional compounds for degrading BTK via ubiquitin proteasome pathway. 2021;WO 2021/091575 A1. https://patentscope.wipo.int/search/en/WO2021091575